Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Biogen Inc. ($BIIB) is a commercial-stage biotechnology firm dedicated to neurological and rare immunological diseases, entered as a new top purchase during the quarter. The manager has taken a bullish position based on the thesis that the business is at an inflection point of a multi-year pipeline transformation that is heavily discounted by the market. The investment rationale hinges on pipeline optionality and high operating leverage inherent to successful commercial biotherapeutic launches. With 10 active programs in Phase 3 development, Biogen has built substantial intellectual property barriers. The recent FDA approval of LEQEMBI IQLIK - an autoinjector enabling at-home subcutaneous administration - removes hospital infusion bottlenecks, dramatically improving unit adoption economics, treatment compliance, and the total addressable market among early-stage Alzheimer's patients. Catalysts across the next 12 to 24 months are plentiful, including Phase 3 data for litifilimab in systemic lupus erythematosus in Q4 2026, subsequent data in cutaneous lupus and kidney rejection in early 2027, and readouts across Parkinson's and Alzheimer's pipelines through mid-2027. Primary risks include clinical trial setbacks across late-stage assets, slower-than-projected diagnostic and treatment infrastructure buildout for Alzheimer's therapies, and commercial reimbursement hurdles.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.